Pathophysiology of hypertension explained

Pathophysiology is a study which explains the function of the body as it relates to diseases and conditions. The pathophysiology of hypertension is an area which attempts to explain mechanistically the causes of hypertension, which is a chronic disease characterized by elevation of blood pressure. Hypertension can be classified by cause as either essential (also known as primary or idiopathic) or secondary. About 90–95% of hypertension is essential hypertension.[1] [2] [3] [4] Some authorities define essential hypertension as that which has no known explanation, while others define its cause as being due to overconsumption of sodium and underconsumption of potassium. Secondary hypertension indicates that the hypertension is a result of a specific underlying condition with a well-known mechanism, such as chronic kidney disease, narrowing of the aorta or kidney arteries, or endocrine disorders such as excess aldosterone, cortisol, or catecholamines. Persistent hypertension is a major risk factor for hypertensive heart disease, coronary artery disease, stroke, aortic aneurysm, peripheral artery disease, and chronic kidney disease.[5]

Cardiac output and peripheral resistance are the two determinants of arterial pressure.[6] Cardiac output is determined by stroke volume and heart rate; stroke volume is related to myocardial contractility and to the size of the vascular compartment. Peripheral resistance is determined by functional and anatomic changes in small arteries and arterioles.

Genetics

Single gene mutations can cause Mendelian forms of high blood pressure;[7] ten genes have been identified which cause these monogenic forms of hypertension.[7] [8] These mutations affect blood pressure by altering kidney salt handling.[9] [10] There is greater similarity in blood pressure within families than between families, which indicates a form of inheritance,[11] and this is not due to shared environmental factors.[12] With the aid of genetic analysis techniques, a statistically significant linkage of blood pressure to several chromosomal regions, including regions linked to familial combined hyperlipidemia, was found.[13] [14] [15] [16] [17] These findings suggest that there are many genetic loci, in the general population, each with small effects on blood pressure. Overall, however, identifiable single-gene causes of hypertension are uncommon, consistent with a multifactorial cause of essential hypertension.[2] [10] [18] [19]

Autonomic nervous system

The autonomic nervous system plays a central role in maintaining cardiovascular homeostasis via pressure, volume, and chemoreceptor signals. It does this by regulating the peripheral vasculature, and kidney function, which in turn affect cardiac output, vascular resistance, and fluid retention. Excess activity of the sympathetic nervous system increases blood pressure and contributes to hypertension.[20] [21] [22] [23] [24]

The mechanisms of increased sympathetic nervous system activity in hypertension involve alterations in baroreflex and chemoreflex pathways at both peripheral and central levels. Arterial baroreceptors are reset to a higher pressure in hypertensive patients, and this peripheral resetting reverts to normal when arterial pressure is normalized.[25] [26] [27] Furthermore, there is central resetting of the aortic baroreflex in hypertensive patients, resulting in suppression of sympathetic inhibition after activation of aortic baroreceptor nerves. This baroreflex resetting seems to be mediated, at least partly, by a central action of angiotensin II.[28] [29] [30] Additional small-molecule mediators that suppress baroreceptor activity and contribute to exaggerated sympathetic drive in hypertension include reactive oxygen species and endothelin.[31] [32] Some studies have shown that hypertensive patients manifest greater vasoconstrictor responses to infused norepinephrine than normotensive controls.[33] And that hypertensive patients do not show the normal response to increased circulating norepinephrinelevels which generally induces downregulation of noradrenergic receptor, and it is believed that this abnormal response is genetically inherited.[34]

Exposure to stress increases sympathetic outflow, and repeated stress-induced vasoconstriction may result in vascular hypertrophy, leading to progressive increases in peripheral resistance and blood pressure.[2] This could partly explain the greater incidence of hypertension in lower socioeconomic groups, since they must endure greater levels of stress associated with daily living. Persons with a family history of hypertension manifest augmented vasoconstrictor and sympathetic responses to laboratory stressors, such as cold pressor testing and mental stress, that may predispose them to hypertension. This is particularly true of young African Americans. Exaggerated stress responses may contribute to the increased incidence of hypertension in this group.[35] For patients having hypertension, higher heart rate variability (HRV) is a risk factor for atrial fibrillation.[36]

Resistant hypertension can be treated by electrically stimulating the baroreflex with a pacemaker-like device.[37]

Renin–angiotensin–aldosterone system

Another system maintaining the extracellular fluid volume, peripheral resistance, and that if disturbed may lead to hypertension, is the renin–angiotensin–aldosterone system. Renin is a circulating enzyme that participates in maintaining extracellular volume and arterial vasoconstriction, therefore contributing to regulation of blood pressure. It performs this function by breaking down (hydrolysing) angiotensinogen, secreted from the liver, into the peptide angiotensin I. Angiotensin I is further cleaved by an enzyme that is located primarily but not exclusively in the pulmonary circulation bound to endothelium; that enzyme is angiotensin converting enzyme (ACE). This cleavage produces angiotensin II, the most vasoactive peptide.[38] [39] Angiotensin II is a potent constrictor of all blood vessels. It acts on the musculature of arteries, raising peripheral resistance and thereby elevating blood pressure. Angiotensin II also causes the adrenal glands to release aldosterone, which stimulates the epithelial cells of the kidneys to increase re-absorption of salt and water, leading to raised blood volume and raised blood pressure. So elevated renin levels in the blood (normally 1.98-2.46 ng/ml in the upright position)[40] leads to hypertension.[2] [41]

Recent studies claim that obesity is a risk factor for hypertension because of activation of the renin–angiotensin system (RAS) in adipose tissue,[42] [43] and also linked renin–angiotensin system with insulin resistance, and claims that anyone can cause the other.[44] Local production of angiotensin II in various tissues, including the blood vessels, heart, adrenals, and brain, is controlled by ACE and other enzymes, including the serine protease chymase. The activity of local renin–angiotensin systems and alternative pathways of angiotensin II formation may make an important contribution to remodeling of resistance vessels and the development of target organ damage (i.e. left ventricular hypertrophy, congestive heart failure, atherosclerosis, stroke, end-stage kidney disease, myocardial infarction, and arterial aneurysm) in hypertensive persons.[41]

Endothelial dysfunction

The endothelium of blood vessels produces an extensive range of substances that influence blood flow and, in turn, is affected by changes in the blood and the pressure of blood flow. For example, local nitric oxide and endothelin, which are secreted by the endothelium, are the major regulators of vascular tone and blood pressure. In patients with essential hypertension, the balance between the vasodilators and the vasoconstrictors is upset, which leads to changes in the endothelium and sets up a "vicious cycle" that contributes to the maintenance of high blood pressure. In patients with hypertension, endothelial activation and damage also lead to changes in vascular tone, vascular reactivity, and coagulation and fibrinolytic pathways. Alterations in endothelial function are a reliable indicator of target organ damage and atherosclerotic disease, as well as prognosis.[45]

Evidence suggests that oxidant stress alters many functions of the endothelium, including modulation of vasomotor tone. Inactivation of nitric oxide (NO) by superoxide and other reactive oxygen species (ROS) seems to occur in conditions such as hypertension.[46] [47] [48] Normally nitric oxide is an important regulator and mediator of numerous processes in the nervous, immune and cardiovascular systems, including smooth muscle relaxation thus resulting in vasodilation of the artery and increasing blood flow, suppressor of migration and proliferation of vascular smooth-muscle cells.[2] It has been suggested that angiotensin II enhances formation of the oxidant superoxide at concentrations that affect blood pressure minimally.[49]

Endothelin is a potent vasoactive peptide produced by endothelial cells that has both vasoconstrictor and vasodilator properties. Circulating endothelin levels are increased in some hypertensive patients,[50] [51] particularly African Americans and persons with hypertension.[50] [52] [53] [54]

Sodium/potassium ratio hypothesis of essential hypertension

A 2007 review article states that while excessive sodium consumption has long been recognized as contributing to the risk of hypertension, "potassium, the main intracellular cation, has usually been viewed as a minor factor in the pathogenesis of hypertension. However, abundant evidence indicates that a potassium deficit has a critical role in hypertension and its cardiovascular sequelae." The authors state that modern, western, high sodium, low potassium diets result in corresponding changes in intracellular concentration of these, the two most important cations in animal cells. This imbalance leads to contraction of vascular smooth muscle, restricting blood flow and so driving up blood pressure. The authors cite studies which show that potassium supplementation is effective in reducing hypertension.[55]

Epidemiological support for this hypothesis can be found in a 2014 meta-analysis which states that "the sodium-to-potassium ratio appears to be more strongly associated with blood pressure outcomes than either sodium or potassium alone in hypertensive adult populations.".[56]

Notes and References

  1. Carretero OA, Oparil S . Essential hypertension. Part I: definition and etiology . . 101 . 3 . 329–35 . January 2000 . 10645931 . 10.1161/01.CIR.101.3.329 . free .
  2. Oparil S, Zaman MA, Calhoun DA . Pathogenesis of hypertension . . 139 . 9 . 761–76 . November 2003 . 14597461 . 10.7326/0003-4819-139-9-200311040-00011. 32785528 .
  3. Book: Hall, John E. . Guyton, Arthur C. . Textbook of medical physiology . limited . Elsevier Saunders . St. Louis, Mo . 2006 . 228 . 978-0-7216-0240-0 .
  4. Web site: Hypertension: eMedicine Nephrology . 2009-06-05 .
  5. Pierdomenico SD, Di Nicola M, Esposito AL, etal . Prognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients . . June 2009 . 19498342 . 10.1038/ajh.2009.103 . 22 . 8 . 842–47. free .
  6. Web site: Cardiovascular Physiology Concepts – Mean Arterial Pressure . 2008-09-29 . Klabunde . Richard E. . 2007 . dead . https://web.archive.org/web/20091002040008/http://www.cvphysiology.com/Blood%20Pressure/BP006.htm . October 2, 2009 .
  7. Lifton RP, Gharavi AG, Geller DS . Molecular mechanisms of human hypertension . . 104 . 4 . 545–56 . February 2001 . 11239411 . 10.1016/S0092-8674(01)00241-0. 9401969 . free .
  8. Wilson FH, Disse-Nicodème S, Choate KA, etal . Human hypertension caused by mutations in WNK kinases . . 293 . 5532 . 1107–12 . August 2001 . 11498583 . 10.1126/science.1062844 . 22700809 .
  9. 10.1126/science.2063193 . Guyton AC . Blood pressure control--special role of the kidneys and body fluids . . 252 . 5014 . 1813–16 . June 1991 . 2063193 . 1991Sci...252.1813G .
  10. Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X . Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel . . 33 . 6 . 1324–31 . June 1999 . 10373210 . 10.1161/01.hyp.33.6.1324 . free .
  11. Feinleib M, Garrison RJ, Fabsitz R, etal . The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results . . 106 . 4 . 284–85 . October 1977 . 562066. 10.1093/oxfordjournals.aje.a112464. 2009-06-08.
  12. Biron P, Mongeau JG, Bertrand D . Familial aggregation of blood pressure in 558 adopted children . . 115 . 8 . 773–74 . October 1976 . 974967 . 1878814 .
  13. Hsueh WC, Mitchell BD, Schneider JL, etal . QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish . . 101 . 24 . 2810–16 . June 2000 . 10859286 . 10.1161/01.cir.101.24.2810. 2009-06-08. free .
  14. Levy D, DeStefano AL, Larson MG, etal . Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study . . 36 . 4 . 477–83 . October 2000 . 11040222 . 10.1161/01.hyp.36.4.477 . free .
  15. Kristjansson K, Manolescu A, Kristinsson A, etal . Linkage of essential hypertension to chromosome 18q . . 39 . 6 . 1044–49 . June 2002 . 12052839 . 10.1161/01.HYP.0000018580.24644.18 . free .
  16. Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF . Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study . . 40 . 1 . 1–6 . July 2002 . 12105129 . 10.1161/01.HYP.0000022660.28915.B1 . free .
  17. Selby JV, Newman B, Quiroga J, Christian JC, Austin MA, Fabsitz RR . Concordance for dyslipidemic hypertension in male twins . . 265 . 16 . 2079–84 . April 1991 . 2013927 . 10.1001/jama.265.16.2079.
  18. Niu T, Yang J, Wang B, et al . Angiotensinogen gene polymorphisms M235T/T174M: no excess transmission to hypertensive Chinese . . 33 . 2 . 698–702 . February 1999 . 10024331 . 10.1161/01.hyp.33.2.698 . free .
  19. Luft FC . Molecular genetics of human hypertension . . 9 . 3 . 259–66 . May 2000 . 10847327 . 10.1097/00041552-200005000-00009.
  20. Somers VK, Anderson EA, Mark AL . Sympathetic neural mechanisms in human hypertension . . 2 . 1 . 96–105 . January 1993 . 7922174 . 10.1097/00041552-199301000-00015.
  21. Takahashi H . [Sympathetic hyperactivity in hypertension] . ja . . 66 . 8 . 1495–502 . August 2008 . 18700548 .
  22. Esler M . The sympathetic system and hypertension . . 13 . 6 Pt 2 . 99S–105S . June 2000 . 10921528 . 10.1016/S0895-7061(00)00225-9. free .
  23. Mark AL . The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure . . 14 . 5 . S159–65 . December 1996 . 9120673 .
  24. Brook RD, Julius S . Autonomic imbalance, hypertension, and cardiovascular risk . . 13 . 6 Pt 2 . 112S–122S . June 2000 . 10921530 . 10.1016/S0895-7061(00)00228-4. free .
  25. Chapleau MW, Hajduczok G, Abboud FM . Mechanisms of resetting of arterial baroreceptors: an overview . . 295 . 4 . 327–34 . April 1988 . 2834951. 10.1097/00000441-198804000-00019.
  26. Guo GB, Thames MD, Abboud FM . Arterial baroreflexes in renal hypertensive rabbits. Selectivity and redundancy of baroreceptor influence on heart rate, vascular resistance, and lumbar sympathetic nerve activity . . 53 . 2 . 223–34 . August 1983 . 6883646 . 10.1161/01.res.53.2.223 . free .
  27. Xie PL, Chapleau MW, McDowell TS, Hajduczok G, Abboud FM . Mechanism of decreased baroreceptor activity in chronic hypertensive rabbits. Role of endogenous prostanoids . . 86 . 2 . 625–30 . August 1990 . 2117025 . 296770 . 10.1172/JCI114754.
  28. Lohmeier TE . The sympathetic nervous system and long-term blood pressure regulation . . 14 . 6 Pt 2 . 147S–154S . June 2001 . 11411750 . 10.1016/S0895-7061(01)02082-9. free .
  29. Guo GB, Abboud FM . Impaired central mediation of the arterial baroreflex in chronic renal hypertension . . 246 . 5 Pt 2 . H720–7 . May 1984 . 6720985 . 10.1152/ajpheart.1984.246.5.H720.
  30. Abboud FM . Effects of sodium, angiotensin, and steroids on vascular reactivity in man . . 33 . 2 . 143–49 . February 1974 . 4359754 .
  31. Li Z, Mao HZ, Abboud FM, Chapleau MW . Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits . . 79 . 4 . 802–11 . October 1996 . 10.1161/01.res.79.4.802 . 2009-06-08 . 8831504 . https://archive.today/20130223063120/http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=8831504 . 2013-02-23 . dead .
  32. Chapleau MW, Hajduczok G, Abboud FM . Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure . . 263 . 1 Pt 2 . R103–8 . July 1992 . 1636777. 10.1152/ajpregu.1992.263.1.R103.
  33. Ziegler MG, Mills P, Dimsdale JE . Hypertensives' pressor response to norepinephrine. Analysis by infusion rate and plasma levels . . 4 . 7 Pt 1 . 586–91 . July 1991 . 1873013 . 10.1093/ajh/4.7.586.
  34. Bianchetti MG, Beretta-Piccoli C, Weidmann P, Ferrier C . Blood pressure control in normotensive members of hypertensive families . . 29 . 4 . 882–88 . April 1986 . 3520094 . 10.1038/ki.1986.81. free .
  35. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S . Normotensive blacks have heightened sympathetic response to cold pressor test . . 22 . 6 . 801–05 . December 1993 . 8244512 . 10.1161/01.hyp.22.6.801 . free .
  36. Kim SH, Lim KR, Chun KJ . Higher heart rate variability as a predictor of atrial fibrillation in patients with hypertensione . . 12 . 1 . 3702 . 2022 . 10.1038/s41598-022-07783-3 . 8904557 . 35260686 .
  37. Wallbach. M. Koziolek. MJ. Baroreceptors in the carotid and hypertension-systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure.. Nephrology, Dialysis, Transplantation. 33. 9. 1485–1493. 9 November 2017. 10.1093/ndt/gfx279. 29136223. free.
  38. Fujino T, Nakagawa N, Yuhki K, etal . Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP . J. Clin. Invest. . 114 . 6 . 805–12 . September 2004 . 15372104 . 516260 . 10.1172/JCI21382 .
  39. Brenner & Rector's The Kidney, 7th ed., Saunders, 2004. pp.2118-2119.Full Text with MDConsult subscription
  40. Hamilton Regional Laboratory Medicine Program - Laboratory Reference Centre Manual. Renin Direct
  41. McConnaughey MM, McConnaughey JS, Ingenito AJ . Practical considerations of the pharmacology of angiotensin receptor blockers . . 39 . 6 . 547–59 . June 1999 . 10354958 . 10.1177/00912709922008155 . 34396502 . 2009-06-09 .
  42. Segura J, Ruilope LM . Obesity, essential hypertension and renin–angiotensin system . . 10 . 10A . 1151–55 . October 2007 . 17903324 . 10.1017/S136898000700064X . free .
  43. Hasegawa H, Komuro I . [The progress of the study of RAAS] . ja . . 67 . 4 . 655–61 . April 2009 . 19348224 .
  44. Saitoh S . [Insulin resistance and renin–angiotensin–aldosterone system] . ja . . 67 . 4 . 729–34 . April 2009 . 19348235 .
  45. Book: O'Brien, Eoin . Beevers, D. G. . Lip, Gregory Y. H. . ABC of hypertension . BMJ Books . London . 2007 . 978-1-4051-3061-5 . registration .
  46. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M . Does superoxide underlie the pathogenesis of hypertension? . . 88 . 22 . 10045–48 . November 1991 . 1658794 . 52864 . 10.1073/pnas.88.22.10045. 1991PNAS...8810045N . free .
  47. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG . Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension . . 95 . 3 . 588–93 . February 1997 . 9024144 . 10.1161/01.cir.95.3.588 . 2009-06-09 . 2013-02-23 . https://archive.today/20130223161308/http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9024144 . dead .
  48. Cai H, Harrison DG . Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress . . 87 . 10 . 840–44 . November 2000 . 11073878 . 10.1161/01.res.87.10.840 . free .
  49. Fukui T, Ishizaka N, Rajagopalan S, etal . p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats . . 80 . 1 . 45–51 . January 1997 . 8978321 . 10.1161/01.res.80.1.45 . 2009-06-09 . https://archive.today/20130223143806/http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=8978321 . 2013-02-23 . dead .
  50. Touyz RM, Schiffrin EL . Role of endothelin in human hypertension . . 81 . 6 . 533–41 . June 2003 . 12839265 . 10.1139/y03-009 . https://archive.today/20121216024620/http://article.pubs.nrc-cnrc.gc.ca/ppv/RPViewDoc?issn=0008-4212&volume=81&issue=6&startPage=533 . dead . 2012-12-16 . 2009-06-09 .
  51. Shreenivas S, Oparil S . The role of endothelin-1 in human hypertension . . 37 . 1–2 . 157–78 . 2007 . 17641406 . 2009-06-09.
  52. Ergul S, Parish DC, Puett D, Ergul A . Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension . . 28 . 4 . 652–5 . October 1996 . 8843893 . 10.1161/01.hyp.28.4.652 . https://archive.today/20130223103334/http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=8843893 . dead . 2013-02-23 . 2009-06-09 .
  53. Grubbs AL, Ergul A . A review of endothelin and hypertension in African-American individuals . . 11 . 4 . 741–48 . 2001 . 11763297 .
  54. Campia U, Cardillo C, Panza JA . Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients . . 109 . 25 . 3191–95 . June 2004 . 15148269 . 10.1161/01.CIR.0000130590.24107.D3 . 2009-06-09. free .
  55. Adrogué. HJ. Madias. NE. Sodium and potassium in the pathogenesis of hypertension.. The New England Journal of Medicine. 10 May 2007. 356. 19. 1966–78. 17494929. 10.1056/NEJMra064486 .
  56. Perez. V. Chang. ET. Sodium-to-potassium ratio and blood pressure, hypertension, and related factors.. Advances in Nutrition. November 2014. 5. 6. 712–41. 25398734. 10.3945/an.114.006783. 4224208.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pathophysiology of hypertension".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.